References

Insights from the 2024 WHO Global Tuberculosis Report - More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goals

10.1016/j.ijid.2024.107325 · 2025 · External reference

The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis

10.1016/s2666-5247(21)00301-3 · 2022 · External reference

The evolving biology of Mycobacterium tuberculosis drug resistance

10.3389/fcimb.2022.1027394 · 2022 · External reference

Evolution of Mycobacterium tuberculosis drug resistance in the genomic era

10.3389/fcimb.2022.954074 · 2022 · External reference

10.1038/nature12337

10.1038/nature12337 · External reference

Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis

10.1038/s41598-018-33370-6 · 2018 · External reference

Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis

10.1128/aac.01024-12 · 2013 · External reference

Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis

10.1016/j.jiph.2018.04.005 · 2018 · External reference

Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis

10.1093/jac/dkq519 · 2011 · External reference

The Structural Basis of Mycobacterium tuberculosis RpoB Drug-Resistant Clinical Mutations on Rifampicin Drug Binding

10.3390/molecules27030885 · 2022 · External reference

Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding

10.1074/jbc.m113.529164 · 2014 · External reference

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery

10.2174/187152607781001763 · 2007 · External reference

Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase

10.1073/pnas.1525055113 · 2016 · External reference

Machine learning-based approach for identification of new resistance associated mutations from whole genome sequences of Mycobacterium tuberculosis

10.1093/bioadv/vbaf050 · 2025 · External reference

10.1038/31159

10.1038/31159 · External reference

The Gene Ontology knowledgebase in 2023

2023 · External reference

10.1021/acs.jcim.1c00203

10.1021/acs.jcim.1c00203 · External reference

10.1093/nar/gky427

10.1093/nar/gky427 · External reference

PATRIC as a unique resource for studying antimicrobial resistance

10.1093/bib/bbx083 · 2019 · External reference

A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics

10.1371/journal.pbio.3001721 · 2022 · External reference

Unresolved reference

External reference

Pfam: multiple sequence alignments and HMM-profiles of protein domains

10.1093/nar/26.1.320 · 1998 · External reference

10.1093/bioinformatics/btt691

10.1093/bioinformatics/btt691 · External reference

Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates

10.1038/ja.2015.9 · 2015 · External reference

Increased expression of efflux pump genes in extensively drug-resistant isolates of Mycobacterium tuberculosis

10.1016/j.ijmyco.2016.09.067 · 2016 · External reference

Three genes controlling streptomycin susceptibility in Agrobacterium fabrum

10.1128/jb.00165-23 · 2023 · External reference

10.1016/j.tube.2017.04.002

10.1016/j.tube.2017.04.002 · External reference

SG-ML-PLAP: A structure-guided machine learning-based scoring function for protein-ligand binding affinity prediction

10.1002/pro.5257 · 2025 · External reference

10.1099/mic.0.26518-0

10.1099/mic.0.26518-0 · External reference

Crystal structure of Mycobacterium tuberculosis polyketide synthase 11 (PKS11) reveals intermediates in the synthesis of methyl-branched alkylpyrones

10.1074/jbc.m113.468892 · 2013 · External reference

Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy

10.1007/978-3-642-14541-4_8 · 2011 · External reference

10.1128/jb.180.22.6068-6071.1998

10.1128/jb.180.22.6068-6071.1998 · External reference

Overexpression of efflux pump genes is one of the mechanisms causing drug resistance in Mycobacterium tuberculosis

10.1128/spectrum.02510-23 · 2024 · External reference

Efflux-mediated drug resistance in bacteria: an update

10.2165/11317030-000000000-00000 · 2009 · External reference

10.1093/nar/gku411

10.1093/nar/gku411 · External reference

Aminoglycosides: An Overview

10.1101/cshperspect.a027029 · 2016 · External reference

Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand

10.1186/1471-2180-14-165 · 2014 · External reference

High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene

10.1128/aac.00851-09 · 2009 · External reference

Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis

10.1128/aac.04438-14 · 2015 · External reference

10.1126/science.aba9102

10.1126/science.aba9102 · External reference

Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations

10.1128/aac.41.8.1677 · 1997 · External reference

Correlation of inhA mutations and ethionamide susceptibility: Experience from national reference center for tuberculosis

10.4103/lungindia.lungindia_120_21 · 2021 · External reference

The Value of the inhA Mutation Detection in Predicting Ethionamide Resistance Using Melting Curve Technology

10.2147/idr.s268799 · 2021 · External reference

High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations

10.1093/jac/dkt090 · 2013 · External reference

EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide

10.3389/fmicb.2017.00710 · 2017 · External reference

Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis

10.5588/ijtld.15.0864 · 2016 · External reference

Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations

10.1038/s41598-018-21378-x · 2018 · External reference

Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis

10.1128/aac.01691-09 · 2010 · External reference

Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables

10.1016/j.ijmyco.2015.09.001 · 2016 · External reference

The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region

10.1093/jac/dks178 · 2012 · External reference

10.1128/aac.01049-15

10.1128/aac.01049-15 · External reference

Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations

10.1128/aac.02583-13 · 2014 · External reference

Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis

10.1073/pnas.1525047113 · 2016 · External reference

Structure guided prediction of Pyrazinamide resistance mutations in pncA

10.1038/s41598-020-58635-x · 2020 · External reference

rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis

10.2147/idr.s333433 · 2021 · External reference

10.1128/jcm.37.8.2663-2666.1999

10.1128/jcm.37.8.2663-2666.1999 · External reference

10.1016/j.molcel.2017.03.001

10.1016/j.molcel.2017.03.001 · External reference

rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico

10.1016/j.jmii.2012.08.020 · 2013 · External reference